Dr. Janessa Patel, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 180 Daggett Dr, West Springfield, MA 01089 Phone: 413-452-4111 |
Thomas Patrick Mangan, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 119 Daggett Drive, West Springfield, MA 01089 Phone: 413-747-5527 Fax: 413-523-4445 |
Longwood Eye, Llc Optometrist Medicare: Medicare Enrolled Practice Location: 180 Daggett Dr, West Springfield, MA 01089 Phone: 413-452-4111 |
Dr. Michael John Gousy, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 120 Westfield St, West Springfield, MA 01089 Phone: 413-733-2318 Fax: 413-732-4824 |
Longwood Eye, Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 180 Daggett Dr, West Springfield, MA 01089 Phone: 413-452-4111 Fax: 413-773-7596 |
News Archive
A Penn State researcher argues that ambiguous international rules outlining when and how governments may "break" pharmaceutical patents may end up significantly reducing incentives for innovation while at the same time failing to increase access to medicines.
People with obesity may have an unexpected ally after weight-loss surgery: their tongues. New research from the Stanford University School of Medicine finds patients who reported a decrease in taste intensity after bariatric surgery had significantly higher excess weight loss after three months than those whose taste intensity became higher.
The U.S. Food and Drug Administration (FDA) today unveiled the nine graphic health warnings required to appear on every pack of cigarettes sold in the United States and in every cigarette advertisement.
As COVID-19 threatens to derail more than a decade's worth of hard-won gains in the fight against malaria, Dr Benjamin Pretorius, managing director at ERADA Technology Alliance, warns that diversions of malaria resources and interruptions to prevention programmes may cost thousands of lives.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office has issued a patent on methods for treating patients with bucindolol based on genetic targeting and focused on a specific genotype - homozygous wildtype for Deletion 322-325 in the alpha-2C adrenergic receptor.
› Verified 8 days ago